2025
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Masri A, Maron M, Abraham T, Nassif M, Barriales-Villa R, Bilen O, Coats C, Elliott P, Garcia-Pavia P, Massera D, Olivotto I, Oreziak A, Owens A, Saberi S, Solomon S, Tower-Rader A, Heitner S, Jacoby D, Melloni C, Wei J, Sherrid M, Olivotto I, Michels M, Barriales-Villa R, Garcia-Pavia P, Abraham T, Choudhury L, Kramer C, Lakdawala N, Maron M, Masri A, Nagueh S, Owens A, Rader F, Saberi S, Sherrid M, Symanski J, Tower-Rader A, Turer A, Wang A, Wong T, Zhang Y, Yang H, Shao C, Yuan Z, Zeng Q, Li X, Ma C, Wang Y, Shu Y, Chen M, Tao L, Li X, Wang J, Yu Z, Cheng X, Hong K, Zemanek D, Bundgaard H, Thune J, Jensen M, Mogensen J, Hagège A, Habib G, Charron P, Lhermusier T, Trochu J, Reant P, Logeart D, Mitrovic V, Bekfani T, Edelman F, Seidler T, Meder B, Schulze P, Stoerk S, Rassaf T, Merkely B, Zfat-Zwas D, Arad M, Halabi M, Paz O, Piltz X, Targetti M, Metra M, Canepa M, Musumeci B, Emdin M, Michels M, Amin A, Knackstedt C, Oreziak A, Wojakowski W, Dudek D, Toste A, Bastos J, Barriales-Villa R, Pavia P, Gimeno Blanes J, Hidalgo Urbano R, Alvarez A, Rincón Diaz L, Ripoll Vera T, Elliott P, Coats C, Cooper R, Mahmod M, Bradlow W, Pantazis A, Tome Esteban M, Masri A, Nassif M, Marian A, Owens D, Wheeler M, McGrew F, Bach R, Wever-Pinzon O, Collado E, Turer A, Hannawi B, Geske J, Owens A, Symanski J, Kramer C, Sarswat N, Ahmad F, Abraham T, Markowitz J, Lakdawala N, Choudhury L, Jani S, Brinkley D, Bilen O, Asher C, Emani S, Sharma A, Fermin D, Lyle M, Raymer D, Darlington A, Maron M, Nielsen C, Wang A, Nagueh S, Martinez M, Desai M, Tower-Rader A, Kelly J, Rader F, Sen S, Bering P, Maurer M, Mitter S, Sherrid M, Wong T, Hussain Z, Saberi S, Naidu S, Enciso J, Zemanek D, Bundgaard H, Jensen M, Mogensen J, Thune J, Donal E, Habib G, Hagege A, Logeart D, Reant P, Trochu J, Brandenburg S, Edelman F, Meder B, Rassaf T, Schulze P, Stoerk S, Merkely B, Arad M, Halabi M, Piltz X, Zfat-Zwas D, Emdin M, Musumeci B, Knackstedt C, Michels M, Oreziak A, Wojakowski W, Bastos J, Toste A, Bradlow W, Coats C, Cooper R, Elliott P, Pantazis A, Raman B, Tome Esteban M, Abraham T, Afshar K, Alsidawi S, Bering P, Bilen O, Brinkley D, Choudhury L, Darlington A, Desai M, Drakos S, Hannawi B, Hussain Z, Kelly J, Kramer C, Lakdawala N, Martinez M, Masri A, Mitter S, Moss N, Nagueh S, Naidu S, Nassif M, Owens A, Rader F, Ravi S, Rowin E, Saberi S, Sen S, Sherrid M, Enciso J, Rader A, Turer A, Wang A, Weiner S, Wong T, Zenker M. Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure 2025, 102441. PMID: 40285763, DOI: 10.1016/j.jchf.2025.03.008.Peer-Reviewed Original ResearchSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyLeft ventricular outflow tractLVOT obstructionOpen-labelHypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathy patientsPlacebo add-on therapyEfficacy of concomitant useEpisodes of atrial fibrillationVentricular outflow tractAdd-on therapyCardiac myosin inhibitorCohort of patientsNegative inotropic propertiesWorsening of symptomsDisopyramide doseBackground therapyPlacebo-ControlledCombination therapyNT-proBNPOutflow tractAficamtenConcomitant useClinical efficacy
2024
Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy
Jadam S, Gaballa A, Alashi A, Xu B, Thamilarasan M, Rodriguez E, Tan C, Ospina S, Smedira N, Popovic Z, Desai M. Association of Histologic Findings With Long-Term Outcomes in Symptomatic Obstructive Hypertrophic Cardiomyopathy Patients Undergoing Surgical Myectomy. JACC Heart Failure 2024, 13: 631-640. PMID: 39545888, DOI: 10.1016/j.jchf.2024.10.006.Peer-Reviewed Original ResearchObstructive hypertrophic cardiomyopathySurgical myectomyLong-term outcomesMyocyte hypertrophyInterstitial fibrosisHistological findingsHypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathy patientsHistological scoresAssociated with long-term outcomesSevere histological findingsHypertrophic cardiomyopathy patientsKaplan-Meier analysisMultivariate Cox analysisLeft ventricular hypertrophyComposite of deathPrimary eventDiastolic dysfunctionCardiac transplantationPrimary endpointTertiary centerCardiomyopathy patientsMicrovascular ischemiaVentricular hypertrophyCox analysis
2022
Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy
Hutt E, Mentias A, Alashi A, Wadhwa R, Fava A, Lever HM, Thamilarasan M, Popovic ZB, Smedira NG, Desai MY. Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardiomyopathy. Progress In Cardiovascular Diseases 2022, 74: 11-18. PMID: 35952727, DOI: 10.1016/j.pcad.2022.08.002.Peer-Reviewed Original ResearchConceptsSeptal reduction therapyBNP ratioNT-proBNP ratioPrimary outcomeAsymptomatic patientsPrognostic valueObstructive hypertrophic cardiomyopathy patientsIncremental prognostic valueNormal NT-proBNPNT-pro BNPObstructive hypertrophic cardiomyopathyLong-term outcomesHypertrophic cardiomyopathy patientsCardiac transplantationNT-proBNPPrimary endpointCardiomyopathy patientsHypertrophic cardiomyopathyReduction therapyHigh riskPatientsDefibrillator dischargeSpline analysisOutcomesBNP
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply